slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 226,891-226,920
Pages 10,126
Rows per page 30
Component
226,891-226,920 of 303,780
52
Includes a standard non-GAAP financial measure disclaimer.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Mece Breakdown1 hit
53
Includes a detailed disclosure paragraph explaining the calculation and use of Segment EBITDA.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Mece Breakdown1 hit
54
Includes footnotes regarding Uni-Select acquisition and Ukraine/Russia conflict impacts.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
55
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
58
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
61
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
62
LKQ | Results Presentation Deck | 62 slidesLKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
01
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
02
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
04
The slide outlines the status of THIO-101, 102, and 103 trials and mentions specific patent filings.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
The slide uses a Gantt-style layout to represent drug development stages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a chromosome icon for the lead asset and a fast-forward icon for the pipeline strategy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
09
This slide serves as a transition or key message reinforcement.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
10
The slide illustrates the interaction between THIO (telomere targeting) and standard checkpoint inhibitor therapies.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Solution1 hit
11
This slide serves as a validation/traction point by highlighting a partnership with a major pharmaceutical company.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
12
The chart shows tumor volume over time, highlighting the efficacy of the THIO + Atezo combination compared to controls.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo across efficacy, safety, and administration metrics.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
15
The slide compares the safety profile of THIO against standard of care (SOC) chemotherapy.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
16
DCR stands for Disease Control Rate. The table compares historical benchmarks (Standard of Care) against the company's clinical trial results (THIO-101).MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
17
Data presented in a table format with footnotes explaining the methodology for DCR calculation.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
18
DCR = Disease Control Rate. Data shows high efficacy across all tested dose levels.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
19
Clinical trial data visualization showing patient-level outcomes over time.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
20
The chart tracks individual patient outcomes over time, including treatment status, response type, and study exit reasons.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
21
The plot highlights long-term benefit post-therapy and low mortality rates in the cohort.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
22
The slide provides visual and quantitative evidence of the drug's mechanism of action (MOA) by showing the increase of TIFs over 72 hours.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
Includes two line charts showing tumor volume reduction and rechallenge success.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit